HUNK Phosphorylates Rubicon to Support Autophagy, Promoting Tumorigenesis in HER2+ Breast Cancer.

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is one of the three clinical subtypes of breast cancer and is defined by having HER2 gene amplification that coincides with HER2 protein overexpression. HER2 is amplified in 15-30% of breast cancers and overexpression of this gene is a predictor of survival in breast cancer patients. HER2-targeted therapies have been successful in treating HER2+ breast cancer; however, over time, HER2+ breast cancer can develop resistance to these therapies. Therefore, there is an urgent need to establish novel targeted agents. One proposed method of resistance to these HER2 agents is dysregulation of autophagy where cancer cells can shift to a cytoprotective autophagy phenotype to avoid cell death. Previous work in our lab established that Hormonally Upregulated Neu-associated kinase (HUNK) is a Serine/Threonine (S/T) protein kinase that is overexpressed in HER2+ breast cancer and is responsible for promoting autophagy, thereby leading to therapeutic resistance. Our previous work shows that HUNK phosphorylates an autophagy protein, Rubicon, in the N-terminal domain at S92, promoting autophagy in 293T cells. However, we have yet to establish a role for this phosphorylation site within HER2+ breast cancer cells. Therefore, the objective of this study is to test whether Rubicon S92 phosphorylation plays a role in promoting tumorigenesis in HER2+ breast cancer. We generated multiple scientific tools: a phosphoserine antibody at S92 in Rubicon, a phospho-mimetic (S92A) mutant, and a phospho-deficient (S92D) mutant. We have established an autophagy phenotype within a HER2/neu model; mouse mammary tumor virus driven neu(rodent form of HER2) expressing mammary tumor cells (MMTV-neu) genetically engineered to be HUNK wild type (WT) or HUNK knockout (KO). We performed an endogenous Rubicon immunoprecipitation (IP) and found that KO cells are deficient in S92 phosphorylation alongside with a lack of autophagy response, measured using LC3-II western blot. These findings confirm that HUNK is required for Rubicon S92 phosphorylation in a genetically tractable model. Utilizing these cell lines alongside the phospho-mimetic and phospho-deficient Rubicon mutants will allow us to determine the role that HUNK plays in promoting tumorigenesis within HER2+ breast cancer in-vitro and in-vivo.